Amgen presented VESALIUS‑CV Phase 3 data showing its PCSK9 monoclonal antibody Repatha reduced major cardiovascular events by 25% when added to standard therapy in high‑risk patients without prior heart attack or stroke. The New England Journal of Medicine publication and AHA presentation reported a 36% reduction in first heart attacks and fewer revascularizations, meeting both primary and key secondary endpoints. The results reinforce the clinical value of potent LDL‑lowering therapies in primary prevention populations and revive discussion about broader use of PCSK9 inhibitors despite cost and access hurdles. The trial could prompt payers and clinicians to reassess thresholds for PCSK9 therapy in selected high‑risk patients.